Padidela, R., Whyte, M. P., Glorieux, F. H., Munns, C. F., Ward, L. M., Nilsson, O., . . . Imel, E. A. (2021). Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. Calcif Tissue Int.
Citação norma ChicagoPadidela, Raja, et al. "Patient-Reported Outcomes From a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children With X-Linked Hypophosphatemia." Calcif Tissue Int 2021.
Citação norma MLAPadidela, Raja, et al. "Patient-Reported Outcomes From a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children With X-Linked Hypophosphatemia." Calcif Tissue Int 2021.